HIV/AIDS Topics Only 1 in 5 Medicaid Users Linked to Care Within a Year After HIV Diagnosis
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
Only about 20% of adult Medicaid recipients who tested positive for HIV during the past decade began receiving appropriate care -- including CDC T-cell count and viral load monitoring -- within a year of diagnosis, and the rate did not improve much within 5 years, according to an analysis described in the January 2013 issue of Sexually Transmitted Diseases.
New HIV NNRTI Lersivirine Matches Efavirenz in Phase 2b Trial
- Details
- Category: HIV Treatment
- Published on Friday, 01 February 2013 00:00
- Written by Liz Highleyman
The investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine suppressed HIV viral load as well as efavirenz (Sustiva) in a 48-week trial, but with a different and side effect profile, researchers reported in the February 1, 2013, Journal of Acquired Immune Deficiency Syndromes.
Kaletra Label Updated to Add Drug Interactions, Including Boceprevir and Telaprevir
- Details
- Category: HIV Treatment
- Published on Thursday, 24 January 2013 00:00
- Written by FDA
Product label information for the HIV protease inhibitor lopinavir/ritonavir (Kaletra) was revised to include information about several additional medications with the potential for drug-drug interactions, the U.S. Food and Drug Administration (FDA) announced last week.
Gilead Starts Phase 3 Trials for New HIV Pro-drug Tenofovir Alafenamide
- Details
- Category: HIV Treatment
- Published on Friday, 01 February 2013 00:00
- Written by Gilead Sciences
Gilead Sciences announced last week that its new single-tablet regimen containing tenofovir alafenamide fumarate (TAF) -- a pro-drug of the widely used tenofovir disoproxil fumarate (TDF) -- has entered the final phase of pre-approval clinical testing.
Very Early HIV Treatment May Delay Disease Progression, Raise CD4 Count
- Details
- Category: HIV Treatment
- Published on Thursday, 24 January 2013 00:00
- Written by Liz Highleyman
Starting antiretroviral therapy (ART) within the first 6 months after infection may slow immune system decline and raise CD4 T-cell counts, but the benefits may not last after treatment is stopped, according to a pair of studies published in January 17, 2013, New England Journal of Medicine.
Complera Label Adds Low Viral Load Restriction, Liver Toxicity Warning
- Details
- Category: HIV Treatment
- Published on Tuesday, 29 January 2013 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week approved revised label information for Complera, Gilead Sciences' tenofovir/emtricitabine/rilpivirine single-tablet regimen. Among the changes, the updated label clarifies that this regimen is indicated for previously untreated people with low baseline viral load, as those with higher levels were more likely to experience treatment failure in clinical trials.
Generic HIV Drugs Could Save Millions, But May Reduce Effectiveness
- Details
- Category: HIV Treatment
- Published on Tuesday, 15 January 2013 00:00
- Written by MGH
Using separate generic pills instead of a brand-name 3-in-1 coformulation could save more than $900 million during the first year, but such a switch could also lead to reduced adherence to antiretroviral therapy (ART) and poorer treatment outcomes, according to a mathematical model described in the January 15, 2013, Annals of Internal Medicine.
More Articles...
- Lancet: Dolutegravir Works as Well as Raltegravir for First-time HIV Treatment
- Poor CD4 Cell Recovery on ART Predicts Non-AIDS Death
- Top 12 HIV and Hepatitis Stories of 2012
- ViiV Submits Integrase Inhibitor Dolutegravir for Approval in the U.S., Europe, and Canada
- HIV11: Lipid Levels Are Higher among HIV+ People on ART, Immune Suppression May Play a Role
Web Design and Development by